| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.WNEU.2018.05.036 |
| P698 | PubMed publication ID | 29772361 |
| P50 | author | Yoshihiro Otani | Q61770130 |
| Atsuhito Uneda | Q83782519 | ||
| Kazuhiko Kurozumi | Q88709333 | ||
| P2093 | author name string | Isao Date | |
| Tomotsugu Ichikawa | |||
| Joji Ishida | |||
| P2860 | cites work | VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex | Q24293027 |
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| The biology of VEGF and its receptors | Q27860704 | ||
| Gliomas and the vascular fragility of the blood brain barrier | Q28081953 | ||
| Structure and function of the blood-brain barrier | Q29615699 | ||
| Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis | Q29620559 | ||
| A randomized trial of bevacizumab for newly diagnosed glioblastoma | Q30410163 | ||
| Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial | Q30744946 | ||
| Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment | Q33475538 | ||
| MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy | Q33616649 | ||
| Integrin inhibitor suppresses bevacizumab-induced glioma invasion | Q33912329 | ||
| Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells. | Q34023246 | ||
| Rapid vascular regrowth in tumors after reversal of VEGF inhibition | Q35052385 | ||
| Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts | Q35102889 | ||
| Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. | Q35823939 | ||
| Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. | Q36179175 | ||
| Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma | Q36544494 | ||
| Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial | Q37240846 | ||
| Angiogenesis as a therapeutic target in malignant gliomas | Q37504362 | ||
| Phenotypic Transition as a Survival Strategy of Glioma. | Q38832371 | ||
| A role for VEGF as a negative regulator of pericyte function and vessel maturation | Q39919369 | ||
| Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. | Q40179252 | ||
| Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. | Q40721144 | ||
| Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy | Q41809732 | ||
| VEGFR-2 Expression in Glioblastoma Multiforme Depends on Inflammatory Tumor Microenvironment. | Q41857963 | ||
| Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours | Q42247667 | ||
| Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab | Q43443828 | ||
| Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. | Q44393459 | ||
| Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. | Q46118866 | ||
| Pathophysiological consequences of VEGF-induced vascular permeability | Q46349878 | ||
| Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma | Q46796397 | ||
| The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET). | Q48175331 | ||
| Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab | Q48787869 | ||
| Bevacizumab changes vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas | Q48940875 | ||
| Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression. | Q54153689 | ||
| Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. | Q55460997 | ||
| Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors | Q78101810 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bevacizumab | Q413299 |
| anaplastic astrocytoma | Q486092 | ||
| P304 | page(s) | 464-471.e1 | |
| P577 | publication date | 2018-05-14 | |
| P1433 | published in | World Neurosurgery | Q26853866 |
| P1476 | title | Comparative Histologic and Molecular Analysis of 2 Recurrent Lesions Showing Different Magnetic Resonance Imaging Responses After Bevacizumab Treatment: Report of a Case of Anaplastic Astrocytoma | |
| P478 | volume | 116 |
Search more.